CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 64 enrolled
Drug / intervention
Liposomal Bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02352922
NCT02352922Phase 4Completed
CompareCT.gov

A Randomized Controlled Trial of Wound Infiltration With Extended-release Versus Short-acting Bupivacaine Before Laparoscopic or Robotic Hysterectomy

AdventHealth·interventional·Posted Feb 2, 2015·Updated Oct 1, 2020

In Brief

A Phase 4 clinical trial evaluating Liposomal Bupivacaine and Bupivacaine HCl for Pain, Postoperative and Surgical Procedure, Unspecified. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The investigators are studying ways to improve pain control after surgery. One way to decrease pain is to inject incisions with a numbing medicine (local anesthetic) while in the operating room. There is an FDA approved extended-release version of a commonly used local anesthetic (bupivacaine) that can last for 4 days instead of 6 hours. The investigators are studying whether using the extended-release medication (Exparel) will give better pain relief after laparoscopic and robotic-assisted hysterectomies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Postoperative, Surgical Procedure, Unspecified
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2, 2015
Enrollment StartJul 1, 2015
Primary CompletionJan 1, 2016
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.4 years ago

Interventions

Liposomal Bupivacainedrug

pre-incision infiltration with liposomal bupivacaine

Bupivacaine HCldrug

pre-incision infiltration with bupivacaine HCl